ArticleCureus2025
Understanding Treatment Completion and Tolerability of Intravesical Bacillus Calmette-Guérin (BCG) for Non-muscle Invasive Bladder Cancer in a Single UK Health Board.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Intravesical Bacillus Calmette-Guérin (BCG) is the standard immunotherapy for high-risk non-muscle invasive bladder cancer (NMIBC). A considerable proportion of patients do not respond adequately to this treatment. This study aims to analyze the rates of and reasons for discontinuation of BCG therapy within a single UK health board. Methods A retrospective study of 40 patients who underwent BCG treatment for NMIBC at Glangwili General Hospital (Hywel Dda University Health Board) from July 2021 to July 2025. Data on patient demographics, tumor characteristics, treatment adherence, and adverse events were collected from medical records. Results Of the 40 patients, 60.0% (n=24) did not complete the full BCG course. Only seven patients (17.5%) exhibited BCG intolerance, grade 2+ toxicities, or related admissions. Smoking status was poorly documented, available for only 10 patients (25.0%). Among these, 15% (n=6) were ex-smokers, 5% (n=2) were current smokers, and 5% (n=2) had never smoked. Adherence to dosing intervals was generally good; 16 of 24 non-completers (66.7%) and 10 of 14 completers (71.4%) received their doses on time (≤14 days). Tumor characteristics showed a high prevalence of high-grade tumors in both non-completers (13/16, 81.3%) and completers (8/10, 80.0%). Conclusion Within our Health Board, BCG failure is multifactorial. It is important to improve data collection, particularly on smoking status and reasons for discontinuation. This will provide us with a more comprehensive understanding of BCG failure and help us improve treatment protocols. A multidisciplinary approach is needed to optimize BCG adherence and effectively manage high-risk NMIBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.